

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/031433 A1

(43) International Publication Date
10 February 2022 (10.02.2022)

(51) International Patent Classification:

A61K 47/54 (2017.01) C12N 15/113 (2010.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2021/042469

(22) International Filing Date:

21 July 2021 (21.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/060,715 04 August 2020 (04.08.2020) US
63/144,603 02 February 2021 (02.02.2021) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Ave, Lexington, MA 02421 (US).

(72) Inventors: **WANG, Weimin**; c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Ave, Lexington, MA 02421 (US). **BROWN, Bob, Dale**; c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Ave, Lexington, MA 02421 (US). **YU, Hongchuan**; c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Ave, Lexington, MA 02421 (US). **CAI, Xiaochuan**; c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Ave, Lexington, MA 02421 (US). **ABRAMS, Marc**; c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Ave, Lexington, MA 02421 (US).

(74) Agent: **DONALDSON, Timothy, B.**; MH2 Technology Law Group, 1951 Kidwell Drive, Suite 310, Tysons Corner, VA 22182 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES

(57) Abstract: The disclosure provides oligonucleotide-ligand conjugates to facilitate the systemic delivery of oligonucleotides designed to prevent, limit or modulate the expression of mRNA molecules. The conjugates comprise nucleotides which are linked to lipid conjugate moieties or adamantyl groups.

WO 2022/031433 A1